Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Core Insights - Valneva reported that antibody levels remained significantly elevated above baseline across all six Lyme disease serotypes and all age groups in the trial [1] Company Summary - Valneva demonstrated strong performance in maintaining antibody levels, indicating potential effectiveness of their Lyme disease treatment across various demographics [1]